Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in High-risk Localized or Locally Advanced Prostate Cancer Candidates for Radical Prostatectomy
2018-001746-34Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Apalutamide + ADT with Placebo + ADT (2 arms). Primary endpoint: Pathological complete response (pCR) rate. Status: unknown.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2018-001746-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001746-34.